Related Experiment Videos

Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation

S J Wagner1, M A Cifone, H Murli

  • 1Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, Maryland, USA.

Transfusion
|May 1, 1995
PubMed
Abstract

Insights

Methylene blue (MB) shows mutagenic effects in cultured mammalian cells but not in vivo. Further research is needed to assess the genotoxic potential of MB in virus inactivation procedures.

Area of Science:

  • Toxicology
  • Genetics
  • Biomedical Science

Background:

  • Virus inactivation procedures for blood products must balance viral risk against treatment risks.
  • Methylene blue (MB), used in Europe for plasma virus inactivation, has shown mutagenic potential in bacterial systems.
  • This study evaluates MB genotoxicity in mammalian models.

Purpose of the Study:

  • To investigate the genotoxic potential of methylene blue (MB) in mammalian cells and in vivo.
  • To assess if MB used for virus inactivation poses a genotoxic risk.

Main Methods:

  • Methylene blue (MB) in heat-treated plasma was tested in an in vitro mouse lymphoma cell assay for gene mutation.
  • The assay was conducted with and without rat liver S9 for metabolic activation.
  • MB in heat-treated plasma was also evaluated using an in vivo mouse micronucleus assay.

Main Results:

  • Methylene blue (MB) significantly increased mutation frequency in mouse lymphoma cells at concentrations of 10 µg/mL (with S9) and 30 µg/mL (without S9).
  • In contrast, intravenous administration of MB at 62 mg/kg did not elevate micronucleus frequency in mouse bone marrow.
  • These results indicate in vitro mutagenicity but no in vivo genotoxicity in the tested systems.

Conclusions:

  • Methylene blue (MB) is mutagenic in cultured mammalian cells.
  • Genotoxicity of MB does not appear to be expressed in vivo based on the mouse micronucleus assay.
  • Further investigation is crucial to fully assess the in vivo genotoxic risk of intravenously administered MB, considering photoproducts and metabolic conversion.

Related Concept Videos